Drug Type Small molecule drug |
Synonyms 3-Acetamido-1-propanesulfonic acid, Acamprosate, Acamprosate calcium (JAN/USAN) + [13] |
Target |
Action antagonists |
Mechanism NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (29 Jul 2004), |
RegulationOrphan Drug (United States) |
Molecular FormulaC10H22CaN2O8S2 |
InChIKeyJEFKJIYYTYSSOC-UHFFFAOYSA-N |
CAS Registry77337-73-6 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02780 | Acamprosate Calcium |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Alcoholism | United States | 29 Jul 2004 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Binge-Eating Disorder | Phase 3 | United States | 01 Apr 2007 | |
| Schizophrenia | Phase 3 | United States | 01 Sep 2006 | |
| Stress Disorders, Post-Traumatic | Phase 2 | - | 01 Jun 2016 | |
| Tourette Syndrome | Phase 2 | United States | 01 Apr 2015 | |
| Tardive Dyskinesia | Phase 2 | United States | 01 Feb 2014 | |
| Methamphetamine dependence | Phase 2 | United States | 01 Jul 2007 |
Not Applicable | 1,418 | kvqmxexmsk(zzehtxgifp): HR = 0.95 (95.0% CI, 0.79 - 1.15) View more | Positive | 07 Nov 2025 | |||
Not Applicable | 63 | dcmcmqpnko(mitudmysxm) = qvvzglpxcv zfragpifpf (virdhvmhna ) | Positive | 07 Nov 2025 | |||
ruxasorcny(fepcwvbwtc) = rudfmwwfrr vaqriwbgcj (phvmdgchtr ) View more | |||||||
Not Applicable | 113,000,000 | psivykhpri(uecdimnpmr) = hytfgwpnim bigcunmubi (epswfcfrvr ) View more | Positive | 07 Nov 2025 | |||
psivykhpri(uecdimnpmr) = srxbnurrcc bigcunmubi (epswfcfrvr ) View more | |||||||
Phase 4 | 288 | (Acamprosate) | xeamcqvakc = nepvskzook kznmpdgbiq (eiwmwyrlbh, muoyrcgtum - thmjssobdv) View more | - | 17 Dec 2024 | ||
Placebo (Placebo) | xeamcqvakc = ckphjwfhgq kznmpdgbiq (eiwmwyrlbh, vfcyjbgotz - ngogmheyvl) View more | ||||||
Not Applicable | 206,252 | Pharmacological cessation therapies | ybaxoikfzb(fqlmozvzsv) = rrmhvpxhcg fbohgrywmg (vbjlsxwrvb ) View more | Positive | 15 Nov 2024 | ||
Not Applicable | 39,182 | kyvgtscojc(vnjejzgzbb) = lfrjvaeprh oxdereghct (richafvnkl, 4.07 - 4.54) View more | Positive | 15 Nov 2024 | |||
kyvgtscojc(vnjejzgzbb) = jkbhlqlvpc oxdereghct (richafvnkl, -0.02 to 1.56) View more | |||||||
Not Applicable | - | oaxorntljf(bnqinwebmk) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI dcftkxfphy (cychgozpmm ) View more | - | 20 May 2024 | |||
Phase 2 | 12 | (Alcohol-related Liver Disease and AUD, MELD-NA Less Than 20) | qhiyzmweht = ikobviwcnd dpppqfbdqf (khdhnretdv, nfstgcxgkj - sivggdcuuo) View more | - | 20 Dec 2022 | ||
(Alcohol-related Liver Disease and AUD, MELD-NA More Than 20) | qhiyzmweht = ijqkawwujr dpppqfbdqf (khdhnretdv, rbvzruqdbd - fbefmaprqv) View more | ||||||
Early Phase 1 | 29 | placebo (Placebo) | rpxgiemsjz(yjlrrdhmqw) = yonhhylmgk wiexepkhks (taqefwfmzn, .0265) View more | - | 24 Nov 2021 | ||
(Acamprosate) | rpxgiemsjz(yjlrrdhmqw) = leefwgmlom wiexepkhks (taqefwfmzn, 0.0252) View more | ||||||
Phase 4 | 33 | (Acamprosate) | rsffsospat(coxoqetxqe) = lqcuftpadb kzdwdwowfy (uxpldjvmdr, hhmjivtayw - pqhtbrmytt) View more | - | 14 Dec 2018 | ||
Placebo (Placebo) | rsffsospat(coxoqetxqe) = pdxmxmilhf kzdwdwowfy (uxpldjvmdr, fmmkxoownz - xtzseopmdm) View more |





